Futura Medical said that all patients had now completed dosing in a European study of a treatment for erectile dysfunction. Futura Medical said it remained on track to deliver headline data from the Phase 3 study by the end of 2019. In addition, patient recruitment had recently been completed for the required 12 month open-label extension study. 'We are extremely pleased to have achieved this important milestone and look forward to the Phase 3 data read out, which is on track to deliver headline efficacy and safety data in December this year, a key value inflection point for the company,' chief executive James Barder said. 'It is estimated that one in six men will experience some form of erectile dysfunction in their lives.' 'We believe MED2005 will offer new hope to erectile dysfunction suffers, in an area that has seen little innovation for nearly two decades and has the potential to be a first line treatment option for erectile dysfunction.' At 1:59pm: (LON:FUM) Futura Medical PLC share price was +2p at 33p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.